39. Daitoku H, Fukamizu A (2007) FOXO transcription factors in the regulatory networks of longevity. J Biochem 141: 769–774. 40. Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795–800. 41. de Boer VC, de Goffau MC, Arts IC, Hollman PC, Keijer J (2006) SIRT1 stimulation by polyphenols is affected by their stability and metabolism. Mech Ageing Dev 127: 618–627. 42. Shankar S, Ganapathy S, Srivastava RK (2008) Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through FOXO-Dependent Regulation of Tumorigenesis regulation of apoptosis, metastasis and angiogenesis. Clinical Cancer Res 14: 1–16. 43. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, et al. (2001) Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073–6083. 44. Furuyama T, Kitayama K, Shimoda Y, Ogawa M, Sone K, et al. (2004) Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem 279: 34741–34749. PLoS ONE | www.plosone.org 12 September 2011 | Volume 6 | Issue 9 | e25166